Aliskiren

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Blood Pressure, High

Conditions

Blood Pressure, High

Trial Timeline

Mar 1, 2010 → Dec 1, 2011

NCT ID

NCT01060865

About Aliskiren

Aliskiren is a approved stage product being developed by Novartis for Blood Pressure, High. The current trial status is terminated. This product is registered under clinical trial identifier NCT01060865. Target conditions include Blood Pressure, High.

What happened to similar drugs?

6 of 16 similar drugs in Blood Pressure, High were approved

Approved (6) Terminated (5) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

✅Aliskiren and HCTZNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

✅Hemostatic MatrixBaxterApproved

✅losartan potassium + Comparator: PlaceboOrganonApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01570686	Approved	Completed	Apr 1, 2012	Nov 1, 2012	Hypertension
NCT01568775	Phase 1	Completed	Jun 1, 2010	Sep 1, 2010	End Stage Renal Disease
NCT01060865	Approved	Terminated	Mar 1, 2010	Dec 1, 2011	Blood Pressure, High
NCT00974922	Approved	Terminated	Aug 1, 2009	Dec 1, 2011	Vitamin D Deficiency
NCT00441064	Approved	Completed	Jan 1, 2007	Nov 1, 2007	Hypertension
NCT00344110	Phase 3	Completed	Jun 1, 2006	Apr 1, 2007	Hypertension
NCT00343551	Phase 3	Completed	May 1, 2006	—	Essential Hypertension
NCT00299832	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Hypertension
NCT00299806	Phase 3	Completed	Apr 1, 2006	Nov 1, 2006	Hypertension
NCT00260923	Phase 3	Completed	Nov 1, 2005	Nov 1, 2006	Hypertension
NCT00262236	Phase 3	Completed	Nov 1, 2005	Aug 1, 2006	Hypertension
NCT00219193	Phase 3	Completed	Oct 1, 2005	Jan 1, 2007	Hypertension
NCT00464880	Phase 1/2	Completed	Sep 1, 2005	Nov 1, 2007	Diabetes Type 2
NCT00461136	Phase 1/2	Completed	Aug 1, 2005	Nov 1, 2006	Diabetes Type 2
NCT00171405	Phase 3	Completed	Jun 1, 2005	Feb 1, 2006	Hypertension
NCT00219102	Phase 3	Completed	Jun 1, 2005	May 1, 2007	Hypertension
NCT00219180	Phase 3	Completed	Jun 1, 2005	Sep 1, 2006	Hypertension
NCT00219011	Phase 3	Completed	May 1, 2005	Feb 1, 2007	Heart Failure
NCT00219167	Phase 3	Completed	Apr 1, 2005	Feb 1, 2006	Hypertension
NCT00219154	Phase 3	Completed	Mar 1, 2005	Jan 1, 2006	Hypertension

Competing Products

20 competing products in Blood Pressure, High

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Phase 1/2	32